12:00 AM
 | 
Dec 08, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Elafin: Phase II data

The investigator-led, double-blind, U.K. Phase II EMPIRE trial in 87 patients undergoing coronary artery bypass graft (CABG) surgery showed that a single pre-operative dose of Elafin did not significantly reduce plasma troponin I AUC from 0-48 hours after surgery vs. placebo. Proteo said “an...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >